Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Zevra Therapeutics, Inc. - Common Stock (NQ: ZVRA ) 6.920 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Zevra Therapeutics, Inc. - Common Stock < Previous 1 2 Next > Beyond The Numbers: 7 Analysts Discuss Zevra Therapeutics Stock September 24, 2024 Via Benzinga Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease September 20, 2024 The FDA has approved Zevra Therapeutics' Miplyffa (arimoclomol) as the first treatment for neurological symptoms of Neimann-Pick disease, type C. This approval follows favorable voting by the Genetic... Via Benzinga Exposures Product Safety Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session August 19, 2024 Via Benzinga 10 Health Care Stocks With Whale Alerts In Today's Session August 15, 2024 Via Benzinga Zevra Therapeutics Mixed Q2 Results: Details August 13, 2024 Zevra Therapeutics reported its second-quarter financial results Tuesday. Here's a look at the details. Via Benzinga Zevra Therapeutics: Q4 Earnings Insights March 28, 2024 Via Benzinga Earnings Outlook For Zevra Therapeutics March 27, 2024 Via Benzinga ZVRA Stock Earnings: Zevra Therapeutics Misses EPS, Beats Revenue for Q2 2024 August 13, 2024 ZVRA stock results show that Zevra Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. Via InvestorPlace PubMatic, Eventbrite, Five9 And Other Big Stocks Moving Lower In Friday's Pre-Market Session August 09, 2024 Via Benzinga Why Kellanova Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket August 05, 2024 Via Benzinga FDA Panel Backs Zevra's Arimoclomol For Rare Genetic Disorder, Analyst Highlights Balanced Portfolio Of Marketed Products And Pipeline Assets Focused On Rare Diseases August 05, 2024 FDA panel supports Zevra Therapeutics' arimoclomol for Niemann-Pick disease type C with an 11-5 vote. William Blair boosts success probability to 90%, highlighting Zevra's growth and balanced rare... Via Benzinga Exposures Product Safety Zevra Therapeutics's Earnings: A Preview November 06, 2023 Via Benzinga 10 Health Care Stocks Whale Activity In Today's Session July 23, 2024 Via Benzinga Insiders Buying Zevra Therapeutics And 1 Other Stock July 18, 2024 Via Benzinga Insiders Buying Barnes & Noble Education And 2 Other Stocks July 17, 2024 Via Benzinga SmallCap Tech/Biotech Stocks July/Aug 2024: ZVSA, DYAI, ZVRA, PRSO, RLMD, VTAK, ENTO, INBS, KAVL July 11, 2024 Via AB Newswire FDA Convenes Expert Panel Meeting For Zevra Therapeutics' Arimoclomol, Analyst Optimistic About Approval Despite Small Patient Base July 09, 2024 FDA's Genetic Metabolic Diseases Advisory Committee will review Zevra Therapeutics' arimoclomol for Niemann-Pick disease type C on August 2. PDUFA decision expected by September 21. Via Benzinga Exposures Product Safety ZVRA Stock Earnings: Zevra Therapeutics Beats EPS, Misses Revenue for Q1 2024 May 08, 2024 ZVRA stock results show that Zevra Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. Via InvestorPlace Zevra Therapeutics, Inc. (NASDAQ: ZVRA) Letter to Stakeholders Looks Like Launch Code to Drive Value May 06, 2024 Via Investor Brand Network ZEVRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Zevra Therapeutics, Inc. on Behalf of Zevra Stockholders and Encourages Investors to Contact the Firm April 03, 2024 From Bragar Eagel & Squire Via GlobeNewswire Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Zevra Therapeutics, Inc. (ZVRA) April 02, 2024 From Kirby McInerney LLP Via GlobeNewswire ZVRA Stock Earnings: Zevra Therapeutics Misses EPS, Beats Revenue for Q4 2023 March 28, 2024 ZVRA stock results show that Zevra Therapeutics missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. Via InvestorPlace Earnings Scheduled For March 28, 2024 March 28, 2024 Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million. Via Benzinga Microsoft To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Thursday December 28, 2023 Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Via Benzinga BioMedNewsBreaks – Zevra Therapeutics Inc. (NASDAQ: ZVRA) Resubmits Arimoclomol New Drug Application to the FDA December 27, 2023 Via Investor Brand Network Exposures Product Safety InvestorNewsBreaks — Zevra Therapeutics Inc. (NASDAQ: ZVRA) Names New President, CEO and Director October 10, 2023 Via Investor Brand Network Topics Retirement Exposures Pension Earnings Scheduled For November 7, 2023 November 07, 2023 Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter. Via Benzinga Health Care Company Zevra Therapeutics Announces Merger With Acer Therapeutics August 31, 2023 Via Benzinga Why Is Acer Therapeutics Stock Trading Higher Today? August 31, 2023 Zevra Therapeutics Inc (NASDAQ: ZVRA) has agreed to acquire Acer Therapeutics Inc (NASDAQ: ACER) for up to $91 million. Via Benzinga BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Acer Therapeutics Inc. (Nasdaq - ACER), Sovos Brands, Inc. (Nasdaq - SOVO), Computer Task Group, Incorporated (Nasdaq - CTG), Decibel Therapeutics, Inc. (Nasdaq - August 31, 2023 From Brodsky & Smith LLC Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.